MannKind shares fall after fire that may delay clinical trial
Shares of MannKind Corp. (MNKD) fell 1.5% premarket on Monday after the biopharma company said a fire at a German manufacturing facility may delay the planned initiation later this year of a phase 2/3 clinical study of MNKD-101, a treatment for nontuberculous myobacterial lung disease. The facility was producing clofazimine inhalation solution, the investigational product that MannKind is developing as MNKD-101, MannKind said in a Securities and Exchange Commission filing Monday. Clinical supplies of MNKD-101 will be delayed an estimated three to six months, according to the filing. The company is "evaluating several mitigation strategies and will update the projected timing for this clinical study at a later date," the filing said.
-Eleanor Laise
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
07-03-23 0828ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom
-
Albemarle Earnings: We Expect Improved Results In the Rest of Year Following Cyclically Low Profits